Compare FLR & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLR | GRFS |
|---|---|---|
| Founded | 1912 | 1940 |
| Country | United States | Spain |
| Employees | N/A | 25247 |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 5.5B |
| IPO Year | 2006 | N/A |
| Metric | FLR | GRFS |
|---|---|---|
| Price | $47.08 | $8.38 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $53.50 | $10.15 |
| AVG Volume (30 Days) | ★ 1.9M | 628.5K |
| Earning Date | 05-08-2026 | 07-28-2022 |
| Dividend Yield | N/A | ★ 1.68% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,503,000,000.00 | N/A |
| Revenue This Year | $6.56 | $4.69 |
| Revenue Next Year | $7.10 | $6.49 |
| P/E Ratio | ★ N/A | $18.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.82 | $6.90 |
| 52 Week High | $57.50 | $11.14 |
| Indicator | FLR | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 47.47 | 51.38 |
| Support Level | $44.70 | $8.27 |
| Resistance Level | $48.90 | $9.78 |
| Average True Range (ATR) | 1.31 | 0.20 |
| MACD | -0.05 | 0.07 |
| Stochastic Oscillator | 23.46 | 53.61 |
Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services.It serves a wide range of end markets, including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $15.5 billion in revenue in 2025.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.